Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics analyses by iMPAQT in sunitinib resistant cells and its HIF2a knock out cells

ABSTRACT: This analysis was performed among 786-o renal cell carcinoma cell line, its sunitinib resistant cell, and sunitinib resistant Hif2a knock out cell.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Hirofumi Yoshino

PROVIDER: PXD007222 | JPOST Repository | Wed Aug 09 00:00:00 BST 2017

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	1-cellmix-1.wiff	Wiff
	1-cellmix-1.wiff.scan	Wiff
	2-786-o-test.wiff	Wiff
	2-786-o-test.wiff.scan	Wiff
	3-786-o-rediSni.wiff	Wiff

Items per page:

1 - 5 of 9

Similar Datasets

786-O and 786-VHL in EMCV study

Project description:786-0 is a cell line derived from a clear cell renal carcinoma. Previous studies have shown that the 786-O cell line harbors an inactivating mutation in the von-Hippel Lindau (VHL) gene. Mutations in the VHL gene occur in the majority of sporadic clear cell renal cell. To determine how inactivation of the VHL affects cellular functions, we created a derivative of 786-0, which we call 786-VHL in which a functional allele of VHL has been introduced back into the 786-O cell line. The renal cell carcinoma cell line 786-0, which harbors a mutated allele of VHL, was compared to a cell line derived from 786-0, termed 786-VHL, that contains a functional allele of VHL. Genes whose expression characteristics were dependent on functional VHL were identified.

2010-06-23 | E-GEOD-22256 | biostudies-arrayexpress

Gene expression profiling of 786-O cells with ZHX2 and p65 knockdown

Project description:We are examining the regulatory pathway of ZHX2 and p65 in clear cell renal cell carcinoma cell line 786-O

2018-06-30 | GSE110094 | GEO

786-O and 786-VHL in EMCV study

2010-06-10 | GSE22256 | GEO

RNA-seq of a VHL-/- human renal cancer cell line 786-0 transfected with 3 vectors

Project description:The human renal cancer cell line 786-0 was transfected with 3 vectors allowing the doxycycline-inducible expression of 1) the full length wild type sequence of VHL: 786-0 VHL WT, VHL+/+, 2) the R167Q mutant : 786-0 R167Q, VHL mutated, 3) the empty vector : 786-0 EV, VHL-/-. The aim of the study was to examine whether the VHL-R167Q mutation, which is associated with a high risk of developping clear cell renal carcinomas, could impact the plasticity of renal carcinoma cells.

2021-12-09 | E-MTAB-11168 | biostudies-arrayexpress

Homo sapiens

Project description:786-0 renal cell carcinoma cell line Everolimus treatment

| PRJNA389812 | ENA

Extracellular vesicles of renal cell carcinoma

Project description:Extracellular vesicles isolated from the supernatant of luciferase-expressing renal cell carcinoma cell line (786-O luc) and its bone metastatic variant (786-O BM) which was established by in vivo selection method. Extracellular vesicles were isolated using MagCapture.

2023-12-28 | PXD039106 | JPOST Repository

Quantitative phosphoproteomics of chronic sunitinib treated renal cell carcinoma 786-O cells with GPR30 agonist G-1

Project description:In this project, we generated chronic sunitinib-treated 786-O cell, a renal cell carcinoma cell line. In order to investigate the possible effect of GPR30 agonist, G-1, on the growth-inhibtion related signaling pathways, we treated either parental both parental and chronic sunitinib-treated 786-O cells were treated either by vehicle-only (i.e. 0.1% DMSO) or 2 μM G-1 for 48 h. Therefore, there were three groups for comparison, including G-1 treatment (G-1 vs. parental), chronic sunitinib-treatment (SunR vs. parental), and G-1 treatment in SunR cells (SunR&G-1 vs. parental).

2021-04-28 | PXD021254 | Pride

Expression data from 786-O renal cell cancer cells treated with pentamidine

Project description:While early stages of clear cell renal cell carcinoma (ccRCC) are curable, survival outcome for metastatic ccRCC remains poor. The purpose of the current study was to apply a new individualized bioinformatics analysis (IBA) strategy to these transcriptome data in conjunction with Gene Set Enrichment Analysis of the Connectivity Map (C-MAP) database to identify and reposition FDA-approved drugs for anti-cancer therapy. We demonstrated that one of the drugs predicted to revert the RCC gene signature towards normal kidney, pentamidine, is effective against RCC cells in culture and in a RCC xenograft model. Most importantly, pentamidine slows tumor growth in the 786-O human ccRCC xenograft mouse model. To determine which genes are regulated by pentamidine in a human RCC cell line, 786-O, we treated these cells with pentamidine and performed transcriptional profiling analysis. We used microarrays to determine the set of genes regulated by pentamidine in 786-O renal cell cancer cells. Total RNA was isolated from 786-O cells treated with 25 Î¼M pentamidine or vehicle control (DMSO) for 6 hours and hybridized to Affymetrix microarrays.

2014-08-05 | E-GEOD-54709 | biostudies-arrayexpress

Next Generation Sequencing from Tumor Tissues And Tumor-adjacent Tissues of Renal Cell Carcinoma

Project description:Tumor-adjacent tissues are very important for tumor research. This study aimed to identify hub genes in tumor-adjacent tissues of mice transplanted with 786-o renal cell carcinoma cells. 786-o cells were implanted in nude mice raised to 1 month of age, and normal tissues, tumor tissues, and adjacent tissues were obtained for RNA sequencing. All tissues were sequenced for transcriptome genes. This was the first systematic exploration of the hub genes in the tumor-adjacent tissues of mice transplanted with 786-o renal cell carcinoma cells, which provides a genetic basis for further in-depth study on the underlying regulatory mechanism of renal cell carcinoma.

2022-02-24 | GSE197100 | GEO

Increased HRD score in cisplatin resistant penile cancer cells

Project description:HRD Score was generated from a penile carcinoma cell line resistant to 5FU and CDDP as well as cross resistant cell line.

2023-11-17 | GSE218782 | GEO